Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

Initial Statement of Beneficial Ownership

Derivative Acquisition Under Employee Benefit Plan

Insider	Title	Date	Shares	% Owned	Market Value
David A. Ricks	Chairman, CEO & President Show All	2025-11-10	734.2K	0.081995%	725.8M
Daniel M. Skovronsky	Chief Scientific & Product Officer and President of Lilly Research Laboratories Show All	2025-11-10	213.1K	0.0238%	210.7M
Anne E. White	Executive VP & President of Lilly Neuroscience Show All	2025-02-12	74.2K	0.008288%	64.7M
Jon Erik Fyrwald	Independent Director Show All	2025-11-18	73.3K	0.008187%	76.9M
Ralph Alvarez	Independent Director Show All	2025-11-18	55.4K	0.006185%	58.1M
Anat Hakim
Edgardo Hernandez
Jacob S. Van Naarden
Ilya Yuffa
Katherine Baicker
William G. Kaelin
Diogo Rau
Juan Ricardo Luciano
Lucas E. Montarce
Eric Dozier
Total			1.4M	0.159871%	1.4B